Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II Study of R3R01 in Alport Syndrome and Primary Steroid-Resistant Focal Segmental Glomerulosclerosis
2021-004192-13Phase 2Active
- Sponsor
- River 3 Renal Corp
- Start
- May 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of R3R01 in Alport syndrome and focal segmental glomerulosclerosis (FSGS), sponsored by River 3 Renal Corp. Primary endpoints: Safety and tolerability, Efficacy (proteinuria reduction) and 1 more. Started May 2022; status: active.
02
Drugs
R3R01
03
Conditions
Alport syndromefocal segmental glomerulosclerosis (FSGS)
Beyond the preview
Go deeper on 2021-004192-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-004192-13.